RedHill Biopharma's Second COVID-19 Candidate, RHB-107, Cleare...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
TEL AVIV, Israel and RALEIGH, N.C., Nov. 17, 2020 /PRNewswire-AsiaNet/ -- FDA clears IND application for Phase 2/3 study with RedHill's second novel COVID-19 candidate, RHB-107 (upamostat), an orally administered novel serine protease inhibitor, with demonstrated antiviral and potential tissue-protective effectsThe ...
Authors: LATEST ASIANET NEWS RELEASES